Key facts
- This page summarizes Venrock Healthcare Capital Partners II, L.P.'s Form 4 filing for Tricida, Inc..
- 3 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 26 Oct 2022, 18:32.
Venrock Healthcare Capital Partners II, L.P. - 24 Oct 2022 Form 4 Insider Report for Tricida, Inc.
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 24 Oct 2022
- Net transaction value
- -$3,501,547
- SEC form
- 4
- Accepted by SEC
- 26 Oct 2022, 18:32:36 UTC
- Prior SEC filing
- 20 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ David L. Stepp, Authorized Signatory
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Venrock Healthcare Capital Partners II, L.P. filed Form 4 for Tricida, Inc. on 26 Oct 2022.
Change
- Previous filing in this sequence was filed on 20 Oct 2022.
- Current net transaction value: -$3,501,547.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TCDA
transaction
Common Stock
Sale
- Transaction value
- $1,289,508
- Shares
- -2,113,948
- Change %
- -21%
- Price
- $0.6100*
- Shares after
- 8,088,998
- Date
- 24 Oct 2022
- Ownership
- By Funds
- Footnotes
- F1, F2, F3
TCDA
transaction
Common Stock
Sale
- Transaction value
- $1,123,138
- Shares
- -1,970,418
- Change %
- -24%
- Price
- $0.5700*
- Shares after
- 6,118,580
- Date
- 25 Oct 2022
- Ownership
- By Funds
- Footnotes
- F3, F4, F5
TCDA
transaction
Common Stock
Sale
- Transaction value
- $1,088,900
- Shares
- -2,367,174
- Change %
- -39%
- Price
- $0.4600*
- Shares after
- 3,751,406
- Date
- 26 Oct 2022
- Ownership
- By Funds
- Footnotes
- F3, F6, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Venrock Healthcare Capital Partners II, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
Consists of (i) 202,708 shares sold by Venrock Healthcare Capital Partners II, L.P. ("VHCP II"), (ii) 82,148 shares sold by VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"), (iii) 617,948 shares sold by Venrock Healthcare Capital Partners III, L.P. ("VHCP III"), (iv) 61,806 shares sold by VHCP Co-Investment Holdings III, LLC ("VHCP Co-3") and (v) 1,149,338 shares sold by Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG").
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.59 to $0.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F3
VHCP Management II, LLC ("VHCPM II") is the general partner of Venrock Healthcare Capital Partners II, L.P. ("VHCP II") and the manager of VHCP Co-Investment Holdings II, LLC ("VHCP Co-2"). VHCP Management III, LLC ("VHCPM III") is the general partner of VHCP III and the manager of VHCP Co-3. VHCP Management EG, LLC ("VHCPM EG") is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCPM II, VHCPM III and VHCPM EG. Each of VHCPM II, VHCPM III, VHCPM EG, Shah and Koh expressly disclaims beneficial ownership over all shares held by VHCP II, VHCP Co-2, VHCP III, VHCP Co-3 and VHCP EG except to the extent of its or his indirect pecuniary interest therein.
Footnote F4
The shares sold on October 25, 2022 consist of (i) 188,945 shares sold by VHCP II, (ii) 76,569 shares sold by VHCP Co-2, (iii) 575,992 shares sold by VHCP III, (iv) 57,610 shares sold by VHCP Co-3 and (v) 1,071,302 shares sold by VHCP EG.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Footnote F6
The shares sold on October 26, 2022 consist of (i) 226,991 shares sold by VHCP II, (ii) 91,988 shares sold by VHCP Co-2, (iii) 691,971 shares sold by VHCP III, (iv) 69,208 shares sold by VHCP Co-3 and (v) 1,287,016 shares sold by VHCP EG.
Footnote F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.43 to $0.53, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.